𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

✍ Scribed by Ivana Sestak; Jack Cuzick; Francisco Sapunar; Richard Eastell; John F Forbes; Angelo R Bianco; Aman U Buzdar


Book ID
117784762
Publisher
The Lancet
Year
2008
Tongue
English
Weight
157 KB
Volume
9
Category
Article
ISSN
1470-2045

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Azacitidine for the treatment of lower r
✍ Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 203 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high‐risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have